Switch theme
Sign up to access all valuation multiples
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.
1993
149
LTM Revenue $7.0M
LTM EBITDA -$152M
-$31.8M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
IGM Biosciences has a last 12-month revenue (LTM) of $7.0M and a last 12-month EBITDA of -$152M.
In the most recent fiscal year, IGM Biosciences achieved revenue of $2.7M and an EBITDA of -$199M.
IGM Biosciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See IGM Biosciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $7.0M | XXX | $2.7M | XXX | XXX | XXX |
| Gross Profit | $7.0M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$152M | XXX | -$199M | XXX | XXX | XXX |
| EBITDA Margin | -2185% | XXX | -7446% | XXX | XXX | XXX |
| EBIT | -$168M | XXX | -$209M | XXX | XXX | XXX |
| EBIT Margin | -2420% | XXX | -7786% | XXX | XXX | XXX |
| Net Profit | -$158M | XXX | -$196M | XXX | XXX | XXX |
| Net Margin | -2269% | XXX | -7309% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, IGM Biosciences's stock price is $1.
IGM Biosciences has current market cap of $76.3M, and EV of -$31.8M.
See IGM Biosciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$31.8M | $76.3M | XXX | XXX | XXX | XXX | $-2.29 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, IGM Biosciences has market cap of $76.3M and EV of -$31.8M.
IGM Biosciences's trades at -11.9x EV/Revenue multiple, and 0.2x EV/EBITDA.
Equity research analysts estimate IGM Biosciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
IGM Biosciences has a P/E ratio of -0.5x.
See valuation multiples for IGM Biosciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $76.3M | XXX | $76.3M | XXX | XXX | XXX |
| EV (current) | -$31.8M | XXX | -$31.8M | XXX | XXX | XXX |
| EV/Revenue | -4.6x | XXX | -11.9x | XXX | XXX | XXX |
| EV/EBITDA | 0.2x | XXX | 0.2x | XXX | XXX | XXX |
| EV/EBIT | 0.2x | XXX | 0.2x | XXX | XXX | XXX |
| EV/Gross Profit | -4.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -0.5x | XXX | -0.4x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 0.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialIGM Biosciences's last 12 month revenue growth is 153%
IGM Biosciences's revenue per employee in the last FY averaged $18K, while opex per employee averaged $1.4M for the same period.
IGM Biosciences's rule of 40 is -11828% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
IGM Biosciences's rule of X is -1803% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for IGM Biosciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 153% | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | -2185% | XXX | -7446% | XXX | XXX | XXX |
| EBITDA Growth | -44% | XXX | -42% | XXX | XXX | XXX |
| Rule of 40 | -11828% | XXX | -7293% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -1803% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $18K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.4M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 6004% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 7886% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
IGM Biosciences acquired XXX companies to date.
Last acquisition by IGM Biosciences was XXXXXXXX, XXXXX XXXXX XXXXXX . IGM Biosciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was IGM Biosciences founded? | IGM Biosciences was founded in 1993. |
| Where is IGM Biosciences headquartered? | IGM Biosciences is headquartered in United States of America. |
| How many employees does IGM Biosciences have? | As of today, IGM Biosciences has 149 employees. |
| Who is the CEO of IGM Biosciences? | IGM Biosciences's CEO is Ms. Mary Beth Harler. |
| Is IGM Biosciences publicy listed? | Yes, IGM Biosciences is a public company listed on NAS. |
| What is the stock symbol of IGM Biosciences? | IGM Biosciences trades under IGMS ticker. |
| When did IGM Biosciences go public? | IGM Biosciences went public in 2019. |
| Who are competitors of IGM Biosciences? | Similar companies to IGM Biosciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of IGM Biosciences? | IGM Biosciences's current market cap is $76.3M |
| What is the current revenue of IGM Biosciences? | IGM Biosciences's last 12 months revenue is $7.0M. |
| What is the current revenue growth of IGM Biosciences? | IGM Biosciences revenue growth (NTM/LTM) is 153%. |
| What is the current EV/Revenue multiple of IGM Biosciences? | Current revenue multiple of IGM Biosciences is -4.6x. |
| Is IGM Biosciences profitable? | Yes, IGM Biosciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of IGM Biosciences? | IGM Biosciences's last 12 months EBITDA is -$152M. |
| What is IGM Biosciences's EBITDA margin? | IGM Biosciences's last 12 months EBITDA margin is -2185%. |
| What is the current EV/EBITDA multiple of IGM Biosciences? | Current EBITDA multiple of IGM Biosciences is 0.2x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
